article thumbnail

Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run

Pharmaceutical Technology

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. The post Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run appeared first on Pharmaceutical Technology.

article thumbnail

Ginkgo buys StrideBio’s AAV discovery and engineering platform assets

Pharmaceutical Technology

Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. As part of the transaction, one StrideBio employee will be transferred to Ginkgo’s mammalian engineering team.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Engineers design sutures that can deliver drugs or sense inflammation

Medical Xpress

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

Drugs 130
article thumbnail

Engineering A Healthier Future: The Power of Tissue Regeneration

Roots Analysis

The Art and Science of Tissue Engineering Do you know that scientists are now able to grow body parts in the lab? This incredible medical breakthrough is called tissue engineering. So, what is tissue engineering? Having said that regenerative grafts created using tissue engineering have numerous applications.

article thumbnail

Genesis raises $200m for AI drug discovery engine

pharmaphorum

Genesis raises $200m for AI drug discovery engine Phil.Taylor Mon, 21/08/2023 - 20:10 Bookmark this

Drugs 96
article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. It is a combination of interferon alfa-2b with interferon gamma.

article thumbnail

CIGB-128 by Center for Genetic Engineering and Biotechnology for Brain Tumor: Likelihood of Approval

Pharmaceutical Technology

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. According to GlobalData, Phase I drugs for Brain Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase I. It is a combination of interferon alfa-2b with interferon gamma.